Long at the forefront of gene-sequencing and -therapy technology, Illumina is picking up steam thanks to the proliferation of DNA sequencing across a variety of medical applications—including tracking infectious diseases like COVID-19. Illumina says there are now some 70 countries using its tech to monitor and analyze samples of the coronavirus, hoping to track how it could mutate into variants. Just as Illumina has helped sharply reduce the cost of genetic sequencing, it aims to do the same for cancer diagnostics via its acquisition of biotech Grail (though the deal faces scrutiny from antitrust regulators).
Courtesy of Illumina
As of 5/23/2022
Scientific, Photographic and Control Equipment
Francis A. deSouza
Market Value ($M)
Market value as of March 31, 2022.
Change the World
Prior Year Rank
|Year||Revenues ($M)||Profits ($M)|
Lists ranking Illumina
Latest news for Illumina
Thera-who? These biotech firms are looking to push what’s possible with bloodOctober 22, 2021, 6:00 PM UTC
Another COVID booster unknown: Will more doses for the vaccinated cause new variants?August 19, 2021, 10:31 PM UTC
Commentary: Attacking Biology’s Complexity with New Genomics ApproachesJanuary 8, 2019, 9:17 PM UTC
These Are the Health Care Companies Poised for Explosive GrowthOctober 18, 2018, 10:31 PM UTC